Traduction de «Mission abroad » (Anglais → Français) :

(Return tabled) Question No. 984 Mr. Pierre Nantel: With regard to Canadian missions abroad (embassies, consulates and delegations within international and regional organizations) and for each of these missions and for fiscal years 2005-2006 to 2012-2013, inclusively: (a) how many positions were related to culture; (b) what were the titles of these positions; (c) where were they located in the mission’s hierarchy; (d) what were the duties of these positions; (e) how many artistic or cultural projects received support from the people occupying these positions; (f) what form of support did the ...[+++]se projects receive; (h) how many Canadian works of art were on display in the rooms of the mission; (i) how many public activities promoting Canadian culture took place and what were these activities; (j) how many private activities promoting Canadian culture took place and what were these activities; and (k) how much of the mission’s budget was allocated to cultural activities or programs, (i) what were the names of these programs, (ii) how much funding was allocated to each of these programs?

47. Notes the responsibility of EU Special Representatives and EU missions abroad in promoting the EU guidelines; encourages a more proactive approach to promoting the guidelines at all levels; underlines the resource and personnel problem within EU missions in third countries concerning guideline awareness, monitoring and implementation; calls on the Member State representations in third countries and the Commission delegations to coordinate more effectively, sharing structures and staff so as to create genuine "European Union embassies" throughout the world and thereby assume responsibilities in the field of hum ...[+++]an rights;

47. Notes the responsibility of EU Special Representatives and EU missions abroad in promoting the EU guidelines; encourages a more proactive approach to promoting the guidelines at all levels; underlines the resource and personnel problem within EU missions in third countries concerning guideline awareness, monitoring and implementation; calls on the Member State representations in third countries and the Commission delegations to coordinate more effectively, sharing structures and staff so as to create genuine "European Union embassies" throughout the world and thereby assume responsibilities in the field of hum ...[+++]an rights;

Q-26 — Mr. Cummins (Delta—South Richmond) — With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many patients were the subject of monitoring reports received by Health Canada directly or indirectly from Roche under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the ...[+++] Lariam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad sinc ...

[Text] Question No. 26 Mr. John Cummins: With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many patients were the subject of monitoring reports received by Health Canada directly or indirectly from Roche under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the La ...[+++]riam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad since 1 ...

7. Calls on the Commission to promote the necessary expertise in gender-relevant policy-making among its staff both at the Commission and at its posts and missions abroad;